复锐医疗科技:销售费用上升拖累业绩,复星系上市公司接连抛出私有化提案

面包财经
21 Jan

复锐医疗科技(1696.HK)是复星医药的大医美核心平台,收入主要来自于能量源设备业务。按区域划分,公司收入主要来自于北美、亚太区。受销售费用率上升等因素影响,公司近年来业绩有所承压。2024年上半年,公司归母净利润同比下降约42%。值得注意的是,2024年以来,复星系两家港股上市公司复宏汉霖、复星旅游文化接连公告私有化提案。复星医药旗下大医美核心平台公开资料显示,复锐医疗科技于2017年在港股...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10